Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Work In Process (2023 - 2025)

Historic Work In Process for Krystal Biotech (KRYS) over the last 3 years, with Q3 2025 value amounting to $15.8 million.

  • Krystal Biotech's Work In Process rose 14727.7% to $15.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.8 million, marking a year-over-year increase of 14727.7%. This contributed to the annual value of $10.7 million for FY2024, which is 23529.96% up from last year.
  • As of Q3 2025, Krystal Biotech's Work In Process stood at $15.8 million, which was up 14727.7% from $15.3 million recorded in Q2 2025.
  • Krystal Biotech's 5-year Work In Process high stood at $15.8 million for Q3 2025, and its period low was $3.2 million during Q4 2023.
  • In the last 3 years, Krystal Biotech's Work In Process had a median value of $7.6 million in 2024 and averaged $9.0 million.
  • As far as peak fluctuations go, Krystal Biotech's Work In Process soared by 23529.96% in 2024, and later skyrocketed by 3942.38% in 2025.
  • Quarter analysis of 3 years shows Krystal Biotech's Work In Process stood at $3.2 million in 2023, then surged by 235.3% to $10.7 million in 2024, then skyrocketed by 47.08% to $15.8 million in 2025.
  • Its last three reported values are $15.8 million in Q3 2025, $15.3 million for Q2 2025, and $8.9 million during Q1 2025.